Skip to Main Content

It was perhaps the most contentious drug approval in decades, shocking drug company executives, insurance companies, and politicians alike: The Food and Drug Administration, over the objections of its scientific advisers, backed the first new Alzheimer’s medication since 2003, one that could finally give millions of dementia patients a reason for optimism — and reap billions of dollars for its manufacturer, Biogen.

After the FDA’s approval of the medicine called Aduhelm three weeks ago, the company’s CEO, Michel Vounatsos, proclaimed on Biogen’s website, “I have hoped for years that we would reach a moment like this.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment